A new study highlights the effectiveness and cost benefits of Myriad™ in low limb salvage procedures. By Investing.com

AUCKLAND, New Zealand, January 16, 2025 /PRNewswire/ — New Zealand Leading soft tissue regeneration company Aroa Biosurgery recently announced the publication of yet another robust clinical trial confirming the cost-effectiveness of its AROA ECM™ technology in high-risk limb-salvage surgery .

Made between May 2022 and April 2023one prospective clinical study included a total of 130 lower limb amputations from 120 patients.

Surprisingly, 95% of patients enrolled in the study had at least one risk factor for amputation, and 55% had 3 or more risk factors for amputation. I was cut off.

Lower limb amputation has the potential to significantly impact quality of life, and the 5-year mortality rate for patients who receive lower limb amputation is ~50%⁽¹⁾.

Published in the December issue of the highly respected peer-reviewed journal, Plastic and reconstructive surgery ” Global Open, a real world study, entitled “Limb Salvage in Ovine Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A Prospective Study”, is the largest prospective study of its kind focusing on the reconstruction of patients with low disability with skin matrix. The study is the first publication in the company’s ongoing study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR).

This study found that AROA’s Myriad Matrix™ and Myriad Morcells™ achieved successful cell protection and replenishment for 30 days, after only one use of the product with no infections or complications reported.

In addition to verifying the use of Myriad products in these low complexity reconstructions⁽²⁾the study highlights the potential for significant cost benefits. Studies have shown an estimated cost difference of up to 195%, compared to other commercially available matrices, when used to build sub-patients.

Founder and CEO of ASX-listeded company, Brian Ward says: “We are very pleased to see the first clinical evidence emerging from our large MASTRR study. The evidence from this study confirms both the effectiveness of, and the potential cost-benefit of related to the use of Myriad in low foot recovery methods. In general the address market of $225 billion⁽³⁾for low-end applications only, this represents a huge oppofor AROA’s sake.”

The principal investigator of the study Dr. John Lawlor is an experienced Foot and Ankle Doctor based in Florida. “I have been using Myriad’s AROA products for several years now and have seen the difference Myriad can make in my patient population. It is very encouraging to see this large study published, measuring significant positive patient outcome, as well as overall cost benefit associated with using Myriad to manage this complex patient population. I’m excited about the opportunity to share our best practices with surgeons,” he says Dr. Lawlor.

(1) Armstrong, DG, et al, Five-year mortality and direct costs of care for people with diabetic foot problems are comparable to cancer. Journal of Foot and Ankle Research2020. 13(1): p. 16.
(2) Bosque, BA, et al. Ovine Forestomach Matrix in the Surgical Management of Complete Low Frequency Obstructions.. Journal of American Podiatric Medicine (TASE:) Organization2023. 113(3).
(3) Estimates of AROA Administration